MX2023007140A - Compuestos farmaceuticos. - Google Patents
Compuestos farmaceuticos.Info
- Publication number
- MX2023007140A MX2023007140A MX2023007140A MX2023007140A MX2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A MX 2023007140 A MX2023007140 A MX 2023007140A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- pharmaceutical compounds
- muscarinic
- agonists
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020191.9A GB202020191D0 (en) | 2020-12-18 | 2020-12-18 | Pharmaceutical compounds |
| PCT/GB2021/053372 WO2022129951A1 (en) | 2020-12-18 | 2021-12-20 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007140A true MX2023007140A (es) | 2023-08-25 |
Family
ID=74221349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007140A MX2023007140A (es) | 2020-12-18 | 2021-12-20 | Compuestos farmaceuticos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11999745B2 (enExample) |
| EP (1) | EP4263536A1 (enExample) |
| JP (1) | JP7730369B2 (enExample) |
| KR (1) | KR20230121830A (enExample) |
| CN (1) | CN116848109B (enExample) |
| AU (1) | AU2021404194A1 (enExample) |
| CA (1) | CA3202054A1 (enExample) |
| CL (1) | CL2023001755A1 (enExample) |
| CO (1) | CO2023007838A2 (enExample) |
| CR (1) | CR20230256A (enExample) |
| DO (1) | DOP2023000125A (enExample) |
| EC (1) | ECSP23044370A (enExample) |
| GB (1) | GB202020191D0 (enExample) |
| IL (1) | IL303484A (enExample) |
| JO (1) | JOP20230128A1 (enExample) |
| MX (1) | MX2023007140A (enExample) |
| PE (1) | PE20240646A1 (enExample) |
| WO (1) | WO2022129951A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039321B (zh) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | 药物化合物 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| EP0786997A4 (en) | 1994-10-27 | 1998-03-11 | Merck & Co Inc | MUSCARINE ANTAGONISTS |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| AU7478496A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
| US5854245A (en) | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| AU3632297A (en) | 1996-08-26 | 1998-03-19 | Pfizer Inc. | Spirocyclic dopamine receptor subtype ligands |
| WO1998057641A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| AU2095099A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists |
| AU2307899A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CZ286152B6 (cs) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparentní a semitransparentní difrakční prvky |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| CZ301161B6 (cs) | 1999-05-04 | 2009-11-18 | Schering Corporation | Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující |
| PT1175224E (pt) | 1999-05-04 | 2005-07-29 | Schering Corp | Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5 |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| NZ518255A (en) | 1999-09-13 | 2004-11-26 | Boehringer Ingelheim Pharma | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| ES2223588T3 (es) | 1999-10-13 | 2005-03-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de imidazolidinona sustituidos. |
| US7163938B2 (en) | 2000-11-28 | 2007-01-16 | Eli Lilly And Company | Substituted carboxamides |
| US7164024B2 (en) | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| NZ533566A (en) | 2001-12-28 | 2007-03-30 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| ATE454381T1 (de) | 2002-03-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Benzofuranderivat |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| WO2004014853A1 (en) | 2002-07-31 | 2004-02-19 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| PT1551835E (pt) | 2002-09-30 | 2007-03-30 | Neurosearch As | Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| PL376925A1 (pl) | 2002-11-27 | 2006-01-09 | Incyte Corporation | Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny |
| JPWO2004069828A1 (ja) | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
| EP1647553A4 (en) | 2003-07-17 | 2008-12-31 | Astellas Pharma Inc | 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF |
| US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| CN1946402A (zh) | 2004-02-05 | 2007-04-11 | 先灵公司 | 用作ccr3拮抗剂的哌啶衍生物 |
| KR100863854B1 (ko) | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ｃｃｒ5 수용체 조절제 |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008521821A (ja) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| JP4774995B2 (ja) | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| WO2006105035A2 (en) | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| WO2006137485A1 (ja) | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| JP2009521483A (ja) | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| AU2007221214A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| EP1987034B1 (en) | 2006-02-22 | 2011-07-20 | Vertex Pharmceuticals Incorporated | Spiro condensed piperidines as modulators of muscarinic receptors |
| AU2007284548A1 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP2010513357A (ja) | 2006-12-22 | 2010-04-30 | ノバルティス アーゲー | Ｄｐｐ−ｉｖ阻害剤としての１−アミノメチル−１−フェニル−シクロヘキサン誘導体 |
| WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| JP5564033B2 (ja) | 2008-03-27 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体 |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| DK2379525T3 (en) | 2008-12-19 | 2015-10-19 | Boehringer Ingelheim Int | Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
| NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2011112825A2 (en) | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| JP2013525370A (ja) | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | PROLYLCARBOXYPEPTIDASE INHIBITORS |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| EP2576520A1 (en) | 2010-05-28 | 2013-04-10 | GE Healthcare UK Limited | Radiolabeled compounds and methods thereof |
| BR112013006344A2 (pt) | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| CN104039321B (zh) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | 药物化合物 |
| DK2897948T3 (en) | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| CN105189482A (zh) | 2013-02-07 | 2015-12-23 | 武田药品工业株式会社 | 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯 |
| EP3102568B1 (en) | 2014-02-06 | 2018-06-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PL3265459T3 (pl) | 2015-02-13 | 2019-09-30 | Suven Life Sciences Limited | Związki amidowe jako agoniści receptora 5-HT4 |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2020
- 2020-12-18 GB GBGB2020191.9A patent/GB202020191D0/en not_active Ceased
-
2021
- 2021-12-20 WO PCT/GB2021/053372 patent/WO2022129951A1/en not_active Ceased
- 2021-12-20 JP JP2023536899A patent/JP7730369B2/ja active Active
- 2021-12-20 CR CR20230256A patent/CR20230256A/es unknown
- 2021-12-20 PE PE2023001903A patent/PE20240646A1/es unknown
- 2021-12-20 AU AU2021404194A patent/AU2021404194A1/en active Pending
- 2021-12-20 MX MX2023007140A patent/MX2023007140A/es unknown
- 2021-12-20 CA CA3202054A patent/CA3202054A1/en active Pending
- 2021-12-20 KR KR1020237023911A patent/KR20230121830A/ko active Pending
- 2021-12-20 CN CN202180093050.7A patent/CN116848109B/zh active Active
- 2021-12-20 IL IL303484A patent/IL303484A/en unknown
- 2021-12-20 EP EP21836606.0A patent/EP4263536A1/en active Pending
-
2022
- 2022-07-27 US US17/874,564 patent/US11999745B2/en active Active
-
2023
- 2023-06-06 JO JOJO/P/2023/0128A patent/JOP20230128A1/ar unknown
- 2023-06-15 DO DO2023000125A patent/DOP2023000125A/es unknown
- 2023-06-15 CL CL2023001755A patent/CL2023001755A1/es unknown
- 2023-06-15 CO CONC2023/0007838A patent/CO2023007838A2/es unknown
- 2023-06-15 EC ECSENADI202344370A patent/ECSP23044370A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116848109A (zh) | 2023-10-03 |
| GB202020191D0 (en) | 2021-02-03 |
| PE20240646A1 (es) | 2024-04-04 |
| CL2023001755A1 (es) | 2024-01-05 |
| JOP20230128A1 (ar) | 2023-06-06 |
| CR20230256A (es) | 2023-09-29 |
| DOP2023000125A (es) | 2023-08-31 |
| EP4263536A1 (en) | 2023-10-25 |
| CN116848109B (zh) | 2026-02-10 |
| CA3202054A1 (en) | 2022-06-23 |
| ECSP23044370A (es) | 2023-08-31 |
| AU2021404194A1 (en) | 2023-08-03 |
| US20220380379A1 (en) | 2022-12-01 |
| CO2023007838A2 (es) | 2023-10-30 |
| WO2022129951A1 (en) | 2022-06-23 |
| IL303484A (en) | 2023-08-01 |
| KR20230121830A (ko) | 2023-08-21 |
| AU2021404194A9 (en) | 2024-10-17 |
| US11999745B2 (en) | 2024-06-04 |
| JP2024504252A (ja) | 2024-01-31 |
| JP7730369B2 (ja) | 2025-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230256A (es) | Compuestos farmacéuticos | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| PH12022550611A1 (en) | Brd9 bifunctional degraders and their methods of use | |
| MX2025001312A (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| IN2014KN01075A (enExample) | ||
| ATE453636T1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| UA100459C2 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MX2021011811A (es) | Protacs que degradan el receptor de estrogeno. | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX2009012579A (es) | Antagonistas piridil piperidina del receptor de orexina. | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| MX2024010092A (es) | Inhibidores del nlrp3 | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| PY2221203A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| MX2021003901A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2025006978A (es) | Compuestos heterociclicos y usos de los mismos | |
| ZA202306305B (en) | Pharmaceutical compounds | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| MX2022001516A (es) | Antagonistas del receptor de neuropeptido ff. | |
| EA201992577A1 (ru) | 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |